GeoVax Labs Inc

GeoVax Labs hits EMA green light, fill‑finish completion, and patent allowance for its GEO‑MVA COVID‑19 vaccine, positioning it as a competitive biopharma contender.

GeoVax Labs Inc.’s stock price has plummeted from a 52-week high of $11.18 to $0.866, raising concerns about the company’s future and ability to deliver on its ambitious vaccine development promises.

GeoVax Labs Inc. reported its first quarter 2025 financial results, highlighting progress on its COVID-19 vaccine, Mpox and Smallpox vaccine, and gene-directed enzyme prodrug therapy for cancer treatment.

GeoVax Labs Inc faces financial turmoil, but its recent clinical developments, particularly with Gedeptin, offer a glimmer of hope for the company’s future.

GeoVax Labs Inc. showcases strong clinical results for its COVID-19 vaccine candidate, GEO-CM04S1, and announces key appointments, including a new Vice President of Technical Development, as the company prepares to report its Q1 2025 financial results.